About This Episode
<p>Eli Lilly raised its full-year outlook after strong demand for its diabetes and obesity treatments drove a major jump in revenue and profit.</p><p><br /></p><p>In this episode, we look at how GLP-1 drugs have become one of the most important growth engines in health care—and why the competition to own this market is only getting fiercer.</p><p><br /></p><p>The bigger story is what happens when one product category grows so fast that it reshapes an entire company’s strategy, valuation, and future.</p><p><br /></p><p>Support the Show</p><p><br /></p><p>• Amazon picks: https://amzn.to/4fUGHEm</p><p>• Amazon picks: https://amzn.to/4pUHt8Q</p><p>• Amazon picks: https://amzn.to/45a4MC9</p><p>• Need a website or app? https://hireawebteam.com</p><p>• Support us on Patreon: https://www.patreon.com/c/StageZeroNews?view_as=patron&vanity=StageZeroNews</p><p>• Subscribe on Supercast: https://clubelon.supercast.com/</p><p><br /></p><p>Disclosure: Amazon links may earn a commission from qualifying purchases.</p>